Kidney protection effects of glitazones;Effets néphroprotecteurs des glitazones

Medecine des Maladies Metaboliques

Volumn 1, Issue 4, 2007, Pages 35-39

  Bonnet, F ^a  

^a RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLITAZONE DERIVATIVE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TRANSFORMING GROWTH FACTOR BETA; TROGLITAZONE;

ALBUMINURIA; ARTICLE; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; MONOTHERAPY; NONHUMAN; RENAL PROTECTION; ULTRAFILTRATION; URINARY EXCRETION;

EID: 37349012664     PISSN: 19572557     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1957-2557(07)74140-8     Document Type: Short Survey

References (35)

1. Yang T, Michele DE, Park J, et al. Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. Am J Physiol 1999;277:F966-73.
2. Okada T, Wada J, Hida K, et al. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms. Diabetes 2006;55:1666-77.
3. Fujii M, Takemura R, Yamaguchi M, et al. Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats. Metabolism 1997;46:981-3.
4. Yoshimoto T, Naruse M, Nishikawa M, et al. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol 1997;272:E989-96.
5. Khan O, Riazi S, Hu X, et al. Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone. Am J Physiol Renal Physiol 2005;289:F442-50.
6. Imano E, Kanda T, Nakatani Y, et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998;21:2135-9.
7. Nakamura T, Ushiyama C, Suzuki S, et al. Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria. Diabet Med 2001;18:308-13.
8. Nakamura T, Ushiyama C, Osada S, et al. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism 2001;50:1193-6.
9. Bakris G, Viberti G, Weston WM, et al. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003;17:7-12.
10. Hanefeld M, Brunetti P, Schernthaner GH, et al; QUARTET Study Group. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004;27:141-7.
11. Schernthaner G, Matthews DR, Charbonnel B, et al; Quartet Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004;89:6068-76. Erratum in: J Clin Endocrinol Metab 2005;90:746.
12. Bakris GL, Ruilope LM, McMorn SO, et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens 2006;24:2047-55.
13. Sarafidis PA, Lasaridis AN, Nilsson PM, et al. The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension. Am J Hypertens 2005;18:227-34.
14. Agarwal R, Saha C, Battiwala M, et al. A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. Kidney Int 2005;68:285-92.
15. Goyal A, Crook ED. Thiazolidinediones and progression of renal disease in patients with diabetes. J Investig Med 2006;54:56-61.
16. McCarthy KJ, Routh RE, Shaw W, et al. Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney Int 2000;58:2341-50.
17. Ma LJ, Marcantoni C, Linton MF, et al. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 2001;59:1899-910.
18. Isshiki K, Haneda M, Koya D, et al. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 2000;49:1022-32.
19. Dalla Vestra M, Masiero A, Roiter AM, et al. Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes 2003;52:1031-5.
20. Mundel P, Shankland SJ. Podocyte biology and response to injury. J Am Soc Nephrol 2002;13:3005-15.
21. Guo B, Koya D, Isono M, et al. Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells. Diabetes 2004;53:200-8.
22. Li Y, Wen X, Spataro BC, et al. Hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists. J Am Soc Nephrol 2006;17:54-65.
23. Benkirane K, Viel EC, Amiri F, Schiffrin EL. Peroxisome proliferator-activated receptor gamma regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo. Hypertension 2006;47:102-8.
24. Benkirane K, Amiri F, Diep QN, et al. PPAR-gamma inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1. Am J Physiol Heart Circ Physiol 2006;290:H390-7.
25. Chen K, Chen J, Li D, et al. Angiotensin II regulation of collagen type I expression in cardiac fibroblasts: modulation by PPAR-gamma ligand pioglitazone. Hypertension 2004;44:655-61.
26. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391:82-6.
27. Lee S, Kim W, Kang KP, et al. Agonist of peroxisome proliferator- activated receptor-gamma, rosiglitazone, reduces renal injury and dysfunction in a murine sepsis model. Nephrol Dial Transplant 2005;20:1057-65.
28. Gumieniczek A. Effect of the new thiazolidinedione-pioglitazone on the development of oxidative stress in liver and kidney of diabetic rabbits. Life Sci 2003;74:553-62.
29. Takeda K, Ichiki T, Tokunou T, et al. Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation 2000;102:1834-9.
30. Onozaki A, Midorikawa S, Sanada H, et al. Rapid change of glucose concentration promotes mesangial cell proliferation via VEGF: inhibitory effects of thiazolidinedione. Biochem Biophys Res Commun 2004;317:24-9.
31. Gruden G, Setti G, Hayward A, et al. Mechanical stretch induces monocyte chemoattractant activity via a NF-kappaB-dependent monocyte chemoattractant protein-1-mediated pathway in human mesangial cells: inhibition by rosiglitazone. J Am Soc Nephrol 2005;16:688-96.
32. Parulkar AA, Pendergrass ML, Granda-Ayala R, et al. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001;134:61-71.
33. Pistrosch F, Herbrig K, Kindel B, et al. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 2005;54:2206-11.
34. Nickenig G, Röling J, Strehlow K, et al. Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms. Circulation 1998;98:2453-60.
35. Catalano C, Muscelli E, Quinones Galvan A, et al. Effect of insulin on systemic and renal handling of albumin in nondiabetic and NIDDM subjects. Diabetes 1997;46:868-75.